Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
ArriVent BioPharma, Inc. (AVBP) had Return on Tangible Equity of -11.57% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-35.54M |
|
-- |
|
-- |
|
$38.82M |
|
$-38.82M |
|
$3.28M |
|
$-35.54M |
|
$-35.54M |
|
$-35.54M |
|
$-35.54M |
|
$-35.54M |
|
$-35.54M |
|
$-38.82M |
|
$-38.82M |
|
38.46M |
|
38.46M |
|
$-0.69 |
|
$-0.69 |
|
| Balance Sheet Financials | |
$332.90M |
|
-- |
|
$0.27M |
|
$333.17M |
|
$25.95M |
|
-- |
|
-- |
|
$25.95M |
|
$307.22M |
|
$307.22M |
|
$307.22M |
|
42.45M |
|
| Cash Flow Statement Financials | |
$-160.59M |
|
$-71.23M |
|
$203.06M |
|
$74.29M |
|
$45.54M |
|
$-28.75M |
|
$12.52M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
12.83 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-160.59M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-11.57% |
|
|
Return on Tangible Equity |
-11.57% |
-10.67% |
|
-11.57% |
|
$7.24 |
|
$-4.18 |
|
$-4.18 |
|